Temporospatial genomic profiling in glioblastoma identifies commonly altered core pathways underlying tumor progression.

ABSTRACT:

Background

Tumor heterogeneity underlies resistance and disease progression in glioblastoma (GBM), and tumors most commonly recur adjacent to the surgical resection margins in contrast non-enhancing (NE) regions. To date, no targeted therapies have meaningfully altered overall patient survival in the up-front setting. The aim of this study was to characterize intratumoral heterogeneity in recurrent GBM using bulk samples from primary resection and recurrent samples taken from contrast-enhancing (EN) and contrast NE regions.

Methods

Whole exome and RNA sequencing were performed on matched bulk primary and multiple recurrent EN and NE tumor samples from 16 GBM patients who received standard of care treatment alone or in combination with investigational clinical trial regimens.

SUBMITTER: Blomquist MR 

PROVIDER: S-EPMC7388612 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature